Saarland University

MGISEQ-T7

At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.

Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.

The partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA IVD assays.

The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.

The researchers were able to differentiate among patients with lung cancer, COPD, and health controls using the biomarkers.

NEW YORK (GenomeWeb News) – Blood expression levels of a dozen microRNAs may help in distinguishing individuals affected by Alzheimer's disease from those who aren't, according to a study appearing online today in Genome Biology.

With up to €16 million ($20 million) in funding from the German Federal Ministry of Education and Research, a consortium of 21 German research groups plans to generate 70 reference epigenome maps over the next five years using next-generation sequencing.

Agilent Technologies and Febit this week separately announced expansions to their sequence capture product lines, while Roche NimbleGen discussed plans to grow its seq-cap portfolio by year end.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.